Last reviewed · How we verify
Gadolinium For abdomen
At a glance
| Generic name | Gadolinium For abdomen |
|---|---|
| Also known as | Gadolinium Magnevist® (gadopentetate dimeglumine) |
| Sponsor | ASIS Corporation |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Technical Development of Cardiovascular Magnetic Resonance Imaging (CMR) Using a Low Specific Absorption Rate (SAR) Scanner System (NA)
- PET/MRI of Primary Sclerosing Cholangitis
- Value of [68Ga]Ga-PSMA-11 PET/MRI in the Assessment of Liver Cirrhosis
- Comparison of Contrast Agents in Liver MR for the Detection of Hepatic Metastases (PHASE4)
- Liver Magnetic Resonance Imaging Before Treatment for Rectal Cancer. A Randomised Controlled Trial. (NA)
- Comparative Effectiveness of Gadopiclenol for Evaluation of Adult Congenital Heart Anatomy and Hemodynamics (PHASE3)
- Longitudinal Imaging in Patients With Large Vessel Vasculitis to Predict Further Disease Course
- Role of MRI in Assessment of the Urinary Bladder Wall Post Transurethral Tumor Resection
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gadolinium For abdomen CI brief — competitive landscape report
- Gadolinium For abdomen updates RSS · CI watch RSS
- ASIS Corporation portfolio CI